ImmunityBio, Inc. (IBRX) experienced a significant pre-market surge of 5.02% on Wednesday, reflecting continued positive momentum for the biopharmaceutical company.
The upward movement appears to be driven by sustained positive analyst sentiment, particularly the reaffirmation of a Buy rating on ImmunityBio by HC Wainwright & Co. Such analyst actions frequently influence investor perception and can catalyze stock price movements, especially when a reputable firm maintains a bullish stance on a company's prospects.